Back to search
Locally Advanced Rectal Adenocarcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Locally Advanced Rectal Adenocarcinoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Locally Advanced Rectal Adenocarcinoma trials you may qualify forThis is a prospective, open-label, randomized, parallel-group phase II trial evaluating the efficacy and safety of a low-dose radiotherapy sensitization strateg…
The purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable l…
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
The purpose of this study is to find out whether the combination of botensilimab and balstilimab (BOT/BAL) is a safe and effective treatment that causes few or…
This phase I trial investigates the side effects and best dose of talazoparib when given together with trifluridine/tipiracil for the treatment of patients with…
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS…
This study is designed to explore the hypothesis that in patients with a Locally advanced rectal cancer (LARC) treated with a Total neoadjuvant therapy (TNT) st…
Determine the complete pathologic complete response (pCR) rate in patients with locally advanced rectal adenocarcinoma.
The purpose of this study is to evaluate the safety and clinical activity of combining cemiplimab, cemiplimab/fianlimab, or cemiplimab/REGN7075 with capecitabin…